FIELD: pharmacology, in particular composition and methods for obesity treatment.
SUBSTANCE: claimed composition contains lipase inhibitor, namely orlistat and koniac or glucomannan and pharmaceutically acceptable excipients.
EFFECT: composition preventing gastrointestinal disturbances associated with administration of lipase inhibitor orlistat.
35 cl, 10 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR AND SUCROSE FATTY ACID ESTER | 2002 |
|
RU2271808C2 |
| SOLID LIPID COMPOSITIONS | 2000 |
|
RU2248218C2 |
| NOVEL PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2241462C2 |
| DISPERSION COMPOSITION CONTAINING LIPASE INHIBITORS | 2000 |
|
RU2239428C2 |
| PHARMACEUTIC COMPOSITION, BIOLOGICALLY ACTIVE ADDITIVE AND METHOD OF REDUCING FAT ABSORPTION FROM FOOD | 2009 |
|
RU2412713C2 |
| METHOD FOR PREPARING COMPOSITION | 2001 |
|
RU2244542C2 |
| THERAPEUTIC AGENTS | 1998 |
|
RU2234917C2 |
| COMPOSITION FOR REDUCING ABSORPTION OF DIETARY FAT | 2011 |
|
RU2566050C2 |
| COMPOSITION FOR PREVENTING OR TREATING OBESITY CONTAINING A-LIPOIC ACID AND N-ACETYLCYSTEINE AS ACTIVE INGREDIENTS | 2015 |
|
RU2670612C9 |
| DERIVATIVES OF 1,1-DIOXOTHIOMORPHOLINYLINDOLYL METHANONE FOR USE AS HISTAMINASE MODULATORS | 2006 |
|
RU2412182C2 |
